Pharmacokinetic profiles of sitafloxacin in patients with renal dysfunction Mitsuyosh

• Nakashima Mitsuyoshi

  Hamamatsu Institute of Clinical Pharmacology and Therapeutics

• Kawada Yukimichi

  Gifu University School of Medicine

Bibliographic Information

Other Title

• Sitafloxacinの腎機能障害者における体内動態

Abstract

We compared pharmacokinetic profiles of sitafloxacin (STFX) in patients with renal dysfunction divided into 3 creatinine clearance (C_cr) based groups: mild dysfunction (Group I), moderate dysfunction (Group II), and severe dysfunction (Group III). The area under the blood concentration-time curve (AUC) was 4.66μg·h/mL in Group I, 8.04μg·h/mL in Group II, and 9.95μg·h/mL in Group III after STFX administration (50mg). These results indicate that AUC increased with renal dysfunction severity. The half-life was 7.5h in Group I, 11.5h in Group II, and 16.3h in Group III, and prolonged depending on renal dysfunction severity. Urinary excretion (0-48h) was 48.9% in Group I, 44.7% in Croup II, and 20.1% in Group III, and decreased depending ooreuol dysfuoctin severity. Tbeiocidencmofodverme reactions wax 25%(3/12).<BR>Our results suggest that the STFX dosage and dosing interval be determined with care in patient with renal dysfunction.

Journal

• Japanese Journal of Chemotherapy

  Japanese Journal of Chemotherapy 56 (Supplement1), 21-24, 2008

  Japanese Society of Chemotherapy

Keywords

• sitafloxacin
• renal dysfunction
• pharmacokinetics
• clinical trial

Details

• CRID: 1390001206288101760
• NII Article ID: 10021192761
• NII Article ID: 130004102784
• NII Book ID: AN10472127
• DOI: 10.11250/chemotherapy1995.56.supplement1_21
• ISSN: 18845886
• ISSN: 13407007
• Web Site: https://search.jamas.or.jp/link/ui/2008207505
• Text Lang: ja
• Data Source:
  • JaLC
  • CiNii Articles
• Abstract License Flag: Disallowed